Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow

Prospective RandomizEd Study Comparing Glycoprotein IIb/IIIa Inhibitors VERsus Standard Therapy in PatientS with Myocardial Infarction and Angiographic Evidence of No-reFLOW

Aim of the study is to examine the effects of glycoprotein IIb/IIIa inhibitors on reperfusion success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction and angiographic evidence of no-reflow.

Inclusion Criteria:

• ST-elevation myocardial infarction and non-ST-elevation myocardial infarction <48 h after symptom onset
• Angiographic evidence of no-reflow (Thrombolysis in Myocardial Infarction-flow grade ≤2) after primary percutaneous coronary intervention
• Age ≥18 years
• Informed consent

Exclusion Criteria:

• ST-elevation myocardial infarction and non-ST-elevation myocardial infarction patients with Thrombolysis in Myocardial Infarction-flow 3 after primary percutaneous coronary intervention
• Age ≤18 years
• Known pregnancy, breast-feeding or intend to become pregnant during the study period
• Contraindication for treatment with platelet inhibitors
• Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin
• Active peptic gastric or duodenal ulcer
• History of major surgery (including intracranial or intraspinal) <4 weeks
• Active bleeding or bleeding diathesis
• Stroke <2 years (ischemic and hemorrhagic)
• Known coagulation defect or relevant thrombocytopenia
• Arteriovenous malformations or aneurysm
• Severe liver insufficiency
• Renal insufficiency requiring dialysis
• Uncontrolled hypertension
• Hypertensive retinopathy
• Vasculitis
• Fibrinolysis <12 hours
• Contraindication for cardiac magnetic resonance imaging at study entry
• Patients without informed consent
• Participation in another trial